LRRK2 Mutations and Gene Expression in Parkinson's Disease
Author Information
Author(s): Michael J. Devine, Alice Kaganovich, Mina Ryten, Adamantios Mamais, Daniah Trabzuni, Claudia Manzoni, Philip McGoldrick, Diane Chan, Allissa Dillman, Julia Zerle, Susannah Horan, Jan-Willem Taanman, John Hardy, Jose-Felix Marti-Masso, Daniel Healey, Anthony H. Schapira, Benjamin Wolozin, Rina Bandopadhyay, Mark R. Cookson, Marcel P. van der Brug
Primary Institution: UCL Institute of Neurology
Hypothesis
Do LRRK2 mutations cause alterations in gene expression in cell models and human brain tissue?
Conclusion
The study found no significant alterations in gene expression linked to LRRK2 mutations in various models.
Supporting Evidence
- Gene expression was analyzed in three systems: fibroblasts, brain tissue, and HEK293 cells.
- No significant differences in gene expression were found between LRRK2 mutation carriers and controls.
- Results suggest that LRRK2 mutations do not lead to large changes in gene expression under normal conditions.
Takeaway
The researchers looked at how certain mutations in a gene related to Parkinson's disease affect how genes work, and they found that these mutations don't really change gene activity much.
Methodology
The study analyzed gene expression in fibroblasts from LRRK2 mutation carriers, brain tissue from G2019S mutation carriers, and HEK293 inducible LRRK2 cell lines.
Limitations
The analysis of brain expression was limited by the small number of G2019S brain samples available for mRNA extraction.
Participant Demographics
Included patients with LRRK2 mutations and healthy controls.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website